Cargando…
The evolution of factor VIIa in the treatment of bleeding in haemophilia with inhibitors
The use of activated factor VII (FVIIa) for the treatment of bleeding events in haemophilia patients with inhibitors was first reported over 30 years ago. Since then clinical trials, registries, case series, real‐world experience and an understanding of its mechanism of action have transformed what...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6899648/ https://www.ncbi.nlm.nih.gov/pubmed/31489759 http://dx.doi.org/10.1111/hae.13845 |